Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Fresh from the biotech pipeline—2017

Nature Biotechnology volume 36, pages 131–136 (2018)Cite this article

A positive regulatory environment, combined with a raft of drug approvals that included the first US gene therapy, buoyed the sector in 2017. The FDA's flexibility and focus on marketplace competition is likely to galvanize innovators in the coming year. Chris Morrison reports.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: FDA New drug applications (NDAs) and biologic license approvals 1998–2017.
Figure 2: 2017 Number of FDA-approved NMEs by therapeutic category.
Figure 3: CDER NME approval rates by PDUFA cohort.

Author information

Authors and Affiliations

  1. Chris Morrison, Yardley, Pennsylvania,

    Chris Morrison

Authors
  1. Chris Morrison
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Morrison, C. Fresh from the biotech pipeline—2017. Nat Biotechnol 36, 131–136 (2018). https://doi.org/10.1038/nbt.4068

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.4068

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing